Christopher Ryan's most recent trade in Gevo Inc was a trade of 626,618 Stock Option done . Disclosure was reported to the exchange on June 9, 2025.
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 626,618 | 626,618 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Jun 2025 | 210,084 | 1,720,084 (11%) | 1% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.28 per share. | 30 May 2025 | 73,934 | 1,510,000 (10%) | 0% | 1.3 | 94,783 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 48,400 | - | - | Restricted Stock Units | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 28 Mar 2025 | 24,200 | 24,206 | - | - | Common Stock | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.46 per share. | 28 Mar 2025 | 7,285 | 16,921 | - | 8.5 | 61,631 | Common Stock |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 10,000 | 83,088 (0%) | 0% | 0 | Restricted Stock | |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Mar 2025 | 10,000 | 73,088 (0%) | 0% | 0 | Restricted Stock | |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 26.23 per share. | 03 Mar 2025 | 1,828 | 61,716 (0%) | 0% | 26.2 | 47,948 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 28 Jan 2025 | 163,000 | 163,000 | - | - | Stock Option (Right to Buy) | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Sep 2024 | 10,000 | 1,583,934 (10%) | 0% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 0.76 per share. | 22 Aug 2024 | 84,014 | 1,573,934 (10%) | 0% | 0.8 | 63,632 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 186,700 | 186,700 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Aug 2024 | 72,600 | 72,600 | - | - | Restricted Stock Units | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 0.51 per share. | 06 Aug 2024 | 46,608 | 1,657,948 (11%) | 0% | 0.5 | 23,579 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 0.59 per share. | 31 Jul 2024 | 39,821 | 1,704,556 (11%) | 0% | 0.6 | 23,482 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 550,000 | 550,000 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 22 May 2024 | 550,000 | 1,744,377 (12%) | 3% | 0 | Common Stock | |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2024 | 27,916 | 70,588 (0%) | 0% | 0 | Restricted Stock | |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.09 per share. | 01 Mar 2024 | 2,742 | 56,044 (0%) | 0% | 12.1 | 33,151 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.38 per share. | 23 Aug 2023 | 83,902 | 1,194,377 (8%) | 0% | 1.4 | 115,617 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 266,220 | 1,278,279 (8%) | 1% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 03 Aug 2023 | 266,220 | 266,220 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 1.65 per share. | 28 Jul 2023 | 36,551 | 1,012,059 (6%) | 0% | 1.6 | 60,265 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Purchase of securities on an exchange or from another person at price $ 3.42 per share. | 09 Jun 2023 | 511 | 1,262 | - | 3.4 | 1,748 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 May 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Apr 2023 | 7,802 | 125,915 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 12.55 per share. | 17 Apr 2023 | 2,569 | 123,346 (1%) | 0% | 12.6 | 32,241 | Common Stock, par value $.01 per share |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Mar 2023 | 31,422 | 53,922 (0%) | 0% | 0 | Restricted Stock | |
| Geo Group, Inc. | Christopher D. Ryan | Senior VP, Human Resources | Payment of exercise price or tax liability using portion of securities received from the company at price $ 9.07 per share. | 01 Mar 2023 | 3,351 | 47,536 (0%) | 0% | 9.1 | 30,394 | Common Stock |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2023 | 40,000 | 40,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 749 | 118,338 (1%) | 0% | - | Common Stock, par value $.01 per share | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 31 Jan 2023 | 749 | 749 | - | - | Restricted Stock Units | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 14.48 per share. | 31 Jan 2023 | 225 | 118,113 (1%) | 0% | 14.5 | 3,258 | Common Stock, par value $.01 per share |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 05 Oct 2022 | 25,000 | 25,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Purchase of securities on an exchange or from another person at price $ 11.75 per share. | 13 Sep 2022 | 5,000 | 117,589 (1%) | 0% | 11.8 | 58,750 | Common Stock, par value $.01 per share |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 3.08 per share. | 22 Aug 2022 | 67,406 | 1,048,610 (7%) | 0% | 3.1 | 207,846 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2022 | 234,711 | 1,116,016 (7%) | 1% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jul 2022 | 158,116 | 158,116 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 2.53 per share. | 07 Jul 2022 | 79,145 | 881,305 (6%) | 0% | 2.5 | 200,237 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Sale of securities on an exchange or to another person at price $ 2.59 per share. | 21 Jun 2022 | 51,049 | 960,450 (6%) | 0% | 2.6 | 131,997 | Common Stock |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 748 | 112,589 (1%) | 0% | - | Common Stock, par value $.01 per share | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jun 2022 | 748 | 1,498 | - | - | Restricted Stock Units | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 15 Jun 2022 | 3,918 | 111,841 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 21 Apr 2022 | 27,686 | 117,890 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 17.16 per share. | 21 Apr 2022 | 9,967 | 107,923 (1%) | 0% | 17.2 | 171,034 | Common Stock, par value $.01 per share |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 400,000 | 400,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 08 Mar 2022 | 50,000 | 50,000 | - | - | Stock Option (Right to Buy) | |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Chief Accounting Officer | Purchase of securities on an exchange or from another person at price $ 1.57 per share. | 10 Dec 2021 | 955 | 9,004 | - | 1.6 | 1,499 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 522,900 | 522,900 | - | - | Stock Option | |
| Gevo Inc | Christopher Ryan | President & COO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 20 Aug 2021 | 522,900 | 1,011,499 (6%) | 3% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 6.85 per share. | 06 Jul 2021 | 97,695 | 488,599 (3%) | 0% | 6.9 | 669,211 | Common Stock |
| Gevo Inc | Christopher Ryan | President & COO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 8.02 per share. | 24 Jun 2021 | 36,056 | 586,294 (4%) | 0% | 8.0 | 289,169 | Common Stock |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Jun 2021 | 2,246 | 2,246 | - | - | Restricted Stock Units | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 16 Apr 2021 | 21,831 | 97,408 (1%) | 0% | 0 | Common Stock, par value $.01 per share | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Payment of exercise price or tax liability using portion of securities received from the company at price $ 27.36 per share. | 16 Apr 2021 | 7,204 | 90,204 (1%) | 0% | 27.4 | 197,101 | Common Stock, par value $.01 per share |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Interim CFO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 26 Jan 2021 | 110,000 | 110,000 | - | - | Stock Option (Right to Buy) | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Sale of securities on an exchange or to another person at price $ 30.13 per share. | 14 Jan 2021 | 9,528 | 75,577 (0%) | 0% | 30.1 | 287,079 | Common stock, par value $.01 per share |
| Avalo Therapeutics Inc | Christopher Ryan Sullivan | Interim CFO | Purchase of securities on an exchange or from another person at price $ 2.28 per share. | 10 Dec 2020 | 5,095 | 8,049 | - | 2.3 | 11,606 | Common Stock |
| Gevo Inc | Christopher Ryan | President, COO & CTO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 0.55 per share. | 01 Aug 2020 | 4,652 | 622,350 (4%) | 0% | 0.6 | 2,559 | Common Stock |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Sale of securities on an exchange or to another person at price $ 25.20 per share. | 08 Jul 2020 | 13,400 | 85,105 (1%) | 0% | 25.2 | 337,680 | Common stock, par value $.01 per share |
| Gevo Inc | Christopher Ryan | President, COO & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 06 Jul 2020 | 454,393 | 627,002 (4%) | 3% | 0 | Common Stock | |
| Gevo Inc | Christopher Ryan | President, COO & CTO | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 01 Jul 2020 | 11,631 | 172,609 (1%) | 0% | 0 | Common Stock | |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Sale of securities on an exchange or to another person at price $ 23.64 per share. | 24 Jun 2020 | 55,000 | 110,474 (1%) | 0% | 23.6 | 1,300,200 | Common Stock, par value $.01 per share |
| Gevo Inc | Christopher Ryan | President, COO & CTO | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.08 per share. | 24 Jun 2020 | 35,263 | 160,978 (1%) | 0% | 1.1 | 38,084 | Common Stock |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Sale of securities on an exchange or to another person at price $ 22.00 per share. | 24 Jun 2020 | 14,641 | 165,474 (2%) | 0% | 22 | 322,102 | Common Stock, par value $.01 per share |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jun 2020 | 8,395 | 100,474 (1%) | 0% | 25.0 | 209,959 | Common Stock, par value $.01 per share |
| Lakeland Industries, Inc. | Christopher J. Ryan | Director | Sale of securities on an exchange or to another person at price $ 25.01 per share. | 24 Jun 2020 | 1,605 | 108,869 (1%) | 0% | 25.0 | 40,141 | Common Stock, par value $.01 per share |